Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)

被引：0
|
作者：
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
机构：
[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[5] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] Brown Univ, Legorreta Canc Ctr, Lifespan Canc Inst, Providence, RI USA
[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
[10] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[11] Penn State Univ, Coll Med, Hershey, PA USA
[12] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Univ Colorado, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7021
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
    Bartlett, Nancy L.
    Assouline, Sarit
    Giri, Pratyush
    Schuster, Stephen J.
    Cheah, Chan Y.
    Matasar, Matthew
    Gregory, Gareth P.
    Yoon, Dok Hyun
    Shadman, Mazyar
    Fay, Keith
    Yoon, Sung-Soo
    Panizo, Carlos
    Flinn, Ian
    Johnston, Anna
    Bosch, Francesc
    Sehn, Laurie H.
    Wei, Michael C.
    Yin, Shen
    To, Iris
    Li, Chi-Chung
    Huang, Huang
    Kwan, Antonia
    Penuel, Elicia
    Budde, Lihua E.
    BLOOD ADVANCES, 2023, 7 (17) : 4926 - 4935
  • [22] Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
    Liebers, Nora
    Duell, Johannes
    Norenberg, Daniel
    Kaebisch, Eva
    Kerkhoff, Andrea
    Acker, Fabian
    Fuhrmann, Stephan
    Leng, Corinna
    Welslau, Manfred
    Chemnitz, Jens
    Middeke, Jan Moritz
    Weber, Thomas
    Trappe, Ralf Ulrich
    Pfannes, Roald
    Liersch, Ruediger
    Spoer, Christian
    Gebauer, Niklas
    Fuxius, Stefan
    Caille, Leandra
    Pott, Christiane
    Koenecke, Christian
    Holtick, Udo
    Geer, Thomas
    Keller, Ulrich
    Claus, Rainer
    Mougiakakos, Dimitrios
    Mayer, Stephanie
    Huttmann, Andreas
    Trummer, Arne
    Wulf, Gerald
    Brunnberg, Uta
    Bullinger, Lars
    Hess, Georg
    Mueller-Tidow, Carsten
    Glass, Bertram
    Lenz, Georg
    Dreger, Peter
    Dietrich, Sascha
    BLOOD, 2020, 136
  • [23] Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
    Topp, Max S.
    Eradat, Herbert
    Florschuetz, Axel
    Hochhaus, Andreas
    Wrobel, Tomasz
    Walewski, Jan
    Knopinska-Posluszny, Wanda
    Kanate, Abraham S.
    Lech-Maranda, Ewa
    Brunnberg, Uta
    Chitra, Surya
    Nielsen, Tina G.
    Sellam, Gila
    Shivhare, Mahesh
    Lossos, Izidore S.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 811 - 817
  • [24] Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Eslami, Mohammadreza
    Mehrabi, Mahdi
    Payandeh, Mehrdad
    Saba, Fakhredin
    PLOS ONE, 2024, 19 (08):
  • [25] Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
    Max S. Topp
    Herbert Eradat
    Axel Florschütz
    Andreas Hochhaus
    Tomasz Wrobel
    Jan Walewski
    Wanda Knopinska-Posluszny
    Abraham S. Kanate
    Ewa Lech-Maranda
    Uta Brunnberg
    Surya Chitra
    Tina G. Nielsen
    Gila Sellam
    Mahesh Shivhare
    Izidore S. Lossos
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 811 - 817
  • [26] Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Shi, Yuanfei
    Xu, Yi
    Wang, Jinghan
    Zheng, Xiaolong
    Li, Xueying
    Jin, Jie
    Tong, Hongyan
    Xie, Wanzhuo
    BLOOD, 2023, 142
  • [27] An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma
    Walji, Moneeza
    Assouline, Sarit
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 933 - 942
  • [28] Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis
    Smith, Stephen D.
    Lopedote, Paolo
    Samara, Yazeed
    Mei, Matthew
    Herrera, Alex F.
    Winter, Allison M.
    Hill, Brian T.
    Shadman, Mazyar
    Ujjani, Chaitra
    Lynch, Ryan C.
    Jacobson, Caron A.
    Kim, Austin, I
    Caimi, Paolo
    Milano, Filippo
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 170 - 175
  • [29] Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Dere, Randall C. C.
    Beardsley, Richard L. L.
    Lu, Dan
    Lu, Tong
    Ku, Grace H-W.
    Man, Gabriel
    Nguyen, Van
    Kaur, Surinder
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [30] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
12345